Vaxcyte Inc. (PCVX): Price and Financial Metrics


Vaxcyte Inc. (PCVX): $43.02

-0.20 (-0.46%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

PCVX Stock Price Chart Interactive Chart >

Price chart for PCVX

PCVX Price/Volume Stats

Current price $43.02 52-week high $47.67
Prev. close $43.22 52-week low $16.78
Day low $41.14 Volume 482,904
Day high $43.39 Avg. volume 585,235
50-day MA $36.35 Dividend yield N/A
200-day MA $27.26 Market Cap 3.40B

Vaxcyte Inc. (PCVX) Company Bio


Vaxcyte, Inc. engages in development of vaccines for infectious diseases. It focuses on conjugate vaccines and protein-based vaccines developed through Sutro Biopharma's Xpress CF Platform, a cell-free protein synthesis technology. The company was founded by Grant E. Pickering, Ashish Khanna and Jeff Fairman on November 27, 2013 and is headquartered in San Francisco, CA.


PCVX Latest News Stream


Event/Time News Detail
Loading, please wait...

PCVX Latest Social Stream


Loading social stream, please wait...

View Full PCVX Social Stream

Latest PCVX News From Around the Web

Below are the latest news stories about VAXCYTE INC that investors may wish to consider to help them evaluate PCVX as an investment opportunity.

Vaxcyte (PCVX) Receives a Buy from Needham

E ratio of -17.15.

Carrie Williams on TipRanks | November 8, 2022

Vaxcyte Reports Third Quarter 2022 Financial Results and Provides Business Update

-- Vaxcyte Reported Positive Topline Data from Phase 1/2 Proof-of-Concept Study of its 24-Valent Pneumococcal Conjugate Vaccine (PCV) Candidate Being Investigated for the Prevention of Invasive Pneumococcal Disease (IPD) in Adults Aged 18-64 -- -- Phase 1/2 Study Met Safety, Tolerability and Immunogenicity Objectives; Findings Indicate a Potential Best-in-Class Profile for VAX-24 -- -- Company Advancing VAX-24 in Adult and Pediatric Populations with Submission of Infant Investigational New Drug

Yahoo | November 7, 2022

Vaxcyte to Present at Upcoming Investor Conferences

SAN CARLOS, Calif., Nov. 03, 2022 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases, announced today that Company management will participate in and host one-on-one meetings at the following investor conferences: Guggenheim 4th Annual Immunology and Neurology ConferenceNovember 14-15, 2022 Fireside Chat will take place live on Monday, November 14 at 1:35

Yahoo | November 3, 2022

Drugmakers Fight Over Lucrative Pneumonia Vaccines

The growing $7 billion market is currently dominated by Pfizer, and rivals’ interest in winning more of the business shows the pharmaceutical industry’s renewed focus on vaccines.

Yahoo | October 31, 2022

Vaxcyte, Inc.'s (NASDAQ:PCVX) large institutional owners must be happy as stock continues to impress, up 111% over the past week

Every investor in Vaxcyte, Inc. ( NASDAQ:PCVX ) should be aware of the most powerful shareholder groups. And the group...

Yahoo | October 30, 2022

Read More 'PCVX' Stories Here

PCVX Price Returns

1-mo -0.76%
3-mo 52.34%
6-mo 128.34%
1-year 99.91%
3-year N/A
5-year N/A
YTD 80.83%
2021 -10.46%
2020 N/A
2019 N/A
2018 N/A
2017 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.6346 seconds.